2022 Venom Evolution, Function and Biomedical Applications GRC/GRS

摘要/摘要 动物毒液是已知的最复杂的自然分泌物之一，由多种生物活性物质组成。 化合物通常被称为毒素。尽管它们很复杂，但毒素的分子结构和靶标， 包括受体以及电压和配体门控离子通道，在整个过程中相对保守 动物王国。这些特征使毒液成为一种极其成功的进化创新 组份是发现和开发治疗多种人类疾病的疗法的理想候选者 病理学。目前，有六种蛇毒来源的多肽是商业上可用的药物：止痛药齐康肽； 用于糖尿病的埃塞那肽；用于抗凝的比伐卢定；用于高血压的卡托普利；以及依替非那肽和替罗非班 治疗冠脉综合症。毒液研究正在呈指数级增长，毒液的增加就是明证。 出版物、研讨会、生物医学应用和生物技术初创公司，导致重要的社会- 对社会的经济影响。因此，世界经济论坛最近将Venonomy指定为 四个最有前途的科学前沿之一，世界卫生组织将蛇咬伤归类为 “A类被忽视的热带病”，并启动了一项全球防治战略。 毒蛇咬伤毒液。然而，由于缺乏对许多毒液的了解，毒液的全部潜力仍未被开发。 有毒动物和机会稀缺，无法创建一个专注于 毒液的多样性。毒液广泛存在于动物的生命树中，以至于没有一个单一的会议将专家联系在一起 在有毒动物的基础科学和应用科学中，向那些研究 蛇毒的药理应用。2022年戈登毒液研究会议和研讨会 进化、功能和生物医学应用(毒液-GRC/GRS)旨在通过以下方式克服这些障碍 联合一个由学术和行业专业人士组成的跨学科小组，将毒液作为全球 健康问题和创新健康解决方案的途径，包括替代、非阿片类疼痛管理 战略。我们的目标是评估与药物发现和开发有关的需求和挑战， 确定毒液研究的未来目标，使该领域能够发展并影响生物医学研究和 药物开发，并通过在会议上促进的合作的手稿的特刊， 传播毒液领域的创新未来方向。会议主席正在作出重大努力 为了邀请一个文化、种族和性别多元化的团队，该团队由150名老牌和职业早期教师组成， 博士后研究员和2022年毒液的研究生-GRC/GRS。我们的计划将培养一个 专家社区专注于蛇毒药物发现和研究中的互补和综合主题 发展--与NCCIH相关的关键问题。

Summary/Abstract Animal venoms are among the most complex natural secretions known, comprising a mixture of bioactive compounds often referred to as toxins. Despite their complexity, the molecular structure and targets of toxins, which include receptors and voltage- and ligand-gated ion channels, are relatively conserved throughout the animal kingdom. These features make venom an extremely successful evolutionary innovation whose components are ideal candidates for discovery and development of therapeutics to treat a wide range of human pathologies. Currently, six venom-derived peptides are commercially available drugs: ziconotide for pain; exenatide for diabetes; bivalirudin for anticoagulation; captopril for hypertension; and eptifibatide and tirofiban for coronary syndrome. Venom research is growing exponentially, as evidenced by the increase in venom publications, symposia, biomedical applications and biotech startup companies, leading to important socio- economic impacts on society. As a consequence, the World Economic Forum recently designated Venomics as one of the four most promising frontiers of science, and the World Health Organization classified snakebite as a “Category A Neglected Tropical Disease” and launched a global strategy for prevention and control of snakebite envenoming. Yet, the full potential of venom remains untapped due to a lack of knowledge on many venomous animals and a scarcity of opportunities to create a cohesive research community focused on the diversity of venom. Venom occurs so broadly across the animal tree of life that no single conference links experts in the basic and applied sciences of venomous animals to those investigating the physiological and pharmacological applications of venom. The 2022 Gordon Research Conference and Seminar on Venom Evolution, Function and Biomedical Applications (Venoms-GRC/GRS) aims to overcome these hurdles by coalescing an interdisciplinary group of academic and industry professionals to address venom as both a global health problem and a route to innovation in health solutions, including alternative, non-opioid pain management strategies. Our goals are to evaluate needs and challenges pertaining to drug discovery and development, identify future goals for venom research that will enable the field to grow and impact biomedical research and drug development and, via a special issue of manuscripts from collaborations fostered at the conference, disseminate innovative future directions in the venom field. The conference chairs are making significant efforts to invite a culturally, ethnically, and gender diverse group of 150 established and early-career faculty, postdoctoral fellows, and graduate students to the 2022 Venoms-GRC/GRS. Our program will foster a community of experts focused on complementary and integrative topics in venom drug discovery and development – key issues that are relevant to NCCIH.